NY-PULSESG,-INC.
pulsESGTM, a pioneering software as a service (SaaS) platform offering enterprises a centralized system of record and reference for environmental, social, and governance (ESG) metrics, has announced that Clayton, Dubilier & Rice (CD&R) has engaged pulsESGTM in a collaborative pilot program seeking to enable portfolio companies to make measurable progress toward ESG goals in a way that can be validated and benchmarked by management and stakeholders.
Through the pilot program, pulsESGTM will work to design, test, configure, and improve initiatives to manage vast amounts of ESG data, which is often unstructured and challenging to process, supporting portfolio company efforts to enable greater transparency, assurance, and value creation across stakeholders.
“The pulsESGTM team is excited to provide an integrated, comprehensive, and flexible SaaS platform that will support the efforts of CD&R and its funds’ portfolio companies to define, capture, analyze, derive insight, and improve their ESG footprint,” said Murat Sönmez, pulsESGTM Co-founder and CEO. “We are pleased to be working on this pilot program with CD&R, which is well-recognized for its commitment to operational excellence.”
Led by tech veterans and co-founders Murat Sönmez and Inderjeet Singh, the pulsESGTM platform provides auditable analytics that can be integrated with both the source and destination ESG systems of customers. This level of information empowers enterprises to make more informed ESG decisions using a platform that also provides end-users the flexibility to modify it based on changes in the ESG regulatory landscape and according to their stakeholder needs.
About pulsESGTM
Founded in 2021, pulsESG, Inc. is a public benefit corporation dedicated to empowering purpose-driven enterprises to manage and improve their ESG footprint with an integrated and comprehensive SaaS platform built for compliance tracking and insight.
For more information, see: www.pulsESG.com
LinkedIn: www.linkedin.com/company/pulsESG
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220830005333/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Quectel Unveils Advanced Matter over Thread Modules for Seamless Device Interoperability13.11.2025 10:00:00 CET | Press release
Quectel Wireless Solutions, an end-to-end global IoT solutions provider, today announced the launch of the KGM133S, the first in a range of Matter over Thread modules that provides innovative solutions for applications such as smart door locks, sensors, and lighting, helping the smart home industry overcome connectivity barriers and advance toward a new era of more efficient and seamless development. The KGM133S series modules are built based on the Silicon Labs EFR32MG24 chip, supporting the latest Matter 1.4 protocol. The modules are designed to enable seamless linkage of home devices across ecosystems, including Apple Home, Google Home, Amazon Alexa and Samsung SmartThings. “Protocol fragmentation remains one of the biggest obstacles to seamless smart device connectivity, and the Matter protocol is the key to overcoming it,” said Delbert Sun, Deputy General Manager at Quectel Wireless Solutions. “With our new Matter over Thread modules, we are helping the industry achieve true inter
SBC Medical Group Announces Commencement of Tender Offer for Shares of Waqoo, Inc.13.11.2025 09:57:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that on November 13, 2025, SBC Medical Group Co., Ltd. (the “Tender Offeror”) has resolved to acquire shares of common stock of Waqoo, Inc. (Securities Code: 4937, listed on the Tokyo Stock Exchange Growth Market; the “Target Company”) through a tender offer (the “Tender Offer”) pursuant to the Financial Instruments and Exchange Act of Japan (Act No. 25 of 1948, as amended; the “FIEA”), as described below. The Tender Offeror is a Japanese subsidiary ultimately owned by SBC Medical Group Holdings Incorporated (“SBCHD”), a U.S. corporation listed on NASDAQ and engaged in management support services for medical clinics both domestically and internationally. As of today, the Tender Offeror holds 353,600 shares of the Target Company’s common stock (ownership ratio: 9.49%).
IQM Launches Halocene, a New Quantum Computer Product Line for Error Correction13.11.2025 09:56:00 CET | Press release
IQM Halocene is a new quantum computer product line aimed at error correction development. It will start with a150-qubit system to be delivered by the end of 2026 and extend all the way to 1,000-qubits. The new product line is based on an open and modular error correction stack, which will allow end-users to experiment and run different quantum error correction features. IQM’s goal is to enable users from supercomputing centers, research organizations, and universities to innovate on quantum error correction research with an open platform. IQM has sold more on-premises quantum systems globally than any other manufacturer, and the company expects the new Halocene product line to accelerate its revenue growth further IQM Quantum Computers, a global leader in superconducting quantum computers, today announced the launch of its new product line called IQM Halocene. The new product line is based on open and modular on-premises quantum computers designed for quantum error correction research
JSR Life Sciences Enters Definitive Agreement to Transfer Crown Bioscience to Adicon Holdings Limited13.11.2025 09:45:00 CET | Press release
Strategic Transaction Positions Crown Bioscience for Accelerated Growth in Translational Oncology JSR Life Sciences LLC ("JSR Life Sciences"), a global leader in life sciences materials and services, today announced it has entered into a definitive agreement to transfer Crown Bioscience Inc. ("Crown Bioscience") to Adicon Holdings Limited ("Adicon"), a premier independent clinical laboratory provider in China and a portfolio company of The Carlyle Group. The transaction, subject to customary closing conditions, is expected to close in 2026. This strategic move will enable Crown Bioscience to operate as a standalone entity under Adicon's ownership. Crown Bioscience's comprehensive portfolio of translational oncology services, including its world-leading patient-derived xenograft (PDX) models, tumor organoid platforms, immuno-oncology assays, and bioinformatics solutions, will transition to Adicon, positioning the company to accelerate advancements in precision medicine and drug discover
Ohmium Breaks Barriers: Exceeds 2030 Industry Targets of 10 GW/ton to Achieve 18 GW/ton Iridium Utilization13.11.2025 09:05:00 CET | Press release
Ohmium International Inc., a leading provider of cutting-edge, high-efficiency, and modular Proton Exchange Membrane (PEM) electrolyzers, has surpassed the PEM electrolyzer industry's 2030 target of 10 GW per ton to attain an 18 GW per ton iridium utilization rate. Ohmium has made significant technological advancements which have resulted in reducing its iridium usage by 50% in its Lotus electrolyzer, Mark 2. This enhances the cost-competitiveness of green hydrogen production by reducing the overall cost of its PEM electrolyzers, which have been impacted by the cost of the precious metal, iridium. Dr. Chock Karuppaiah, Ohmium Chief Science and Technology Officer, said, "We've made significant strides in reducing iridium usage in our PEM electrolyzers, exceeding the 2030 industry target of 10 GW per ton. We've achieved a utilization rate of 18 GW per ton. This innovation is crucial, as iridium is one of the most expensive materials in electrolyzer manufacturing.” Dr. Markus Tacke, Ohmiu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom